Vanda Pharmaceuticals has rallied about 62% since mid-November as investors await an FDA decision on tradipitant for motion sickness, a market estimated near $670 million in 2025. The drug previously failed in gastroparesis, but labeling talks are underway. Approval could reshape Vanda outlook and extend the stock sharp recovery this year.